Science Explorer Back to mapMap
Discussion
Institution · Acetylon Pharmaceuticals (United States)

Most cited papers from Acetylon Pharmaceuticals (United States)

Acetylon Pharmaceuticals (United States)

What are the most cited papers from Acetylon Pharmaceuticals (United States)?

The most cited paper from Acetylon Pharmaceuticals (United States) is "Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma" (Loredana Santo, Teru Hideshima, Andrew L. Kung et al., 2012), with 613 citations. Next come "HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients" (389) and "Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance" (306).

Showing 50 of 72 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood Open access 20 Jan 2012 613
2 HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients Wenting Guo et al. · Nature Communications Open access 5 Oct 2017 389
3 Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance Casey N. Cook, Yari Carlomagno, Tania F. Gendron et al. · Human Molecular Genetics Open access 19 Aug 2013 306
4 Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma Dan T. Vogl, Noopur S Raje, Sundar Jagannath et al. · Clinical Cancer Research Open access 4 Jan 2017 256
5 Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial Andrew Jenho Yee, William Bensinger, Jeffrey G. Supko et al. · The Lancet Oncology 17 Sep 2016 204
6 HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy Karen Krukowski, Jiacheng Ma, Olga Golonzhka et al. · Pain Open access 4 Mar 2017 193
7 Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability Jeanine Jochems, Janette Boulden, Bridgin G. Lee et al. · Neuropsychopharmacology Open access 19 Aug 2013 173
8 Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models Pengyu Huang, Ingrid Almeciga-Pinto, Matthew B. Jarpe et al. · Oncotarget Open access Dec 2016 136
9 Transcriptional Regulation of Enhancers Active in Protodomains of the Developing Cerebral Cortex Kartik Pattabiraman, Olga Golonzhka, Susan Lindtner et al. · Neuron Open access 8 May 2014 111
10 Ricolinostat ( ACY ‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death Yuko Matsumoto Mishima, Loredana Santo, Homare Eda et al. · British Journal of Haematology 23 Feb 2015 103
11 Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease Veronick Benoy, Pieter Vanden Berghe, Matthew B. Jarpe et al. · Neurotherapeutics Open access 12 Dec 2016 87
12 HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics Andressa S. Laino, Brian Christopher Betts, Anandharaman Veerapathran et al. · Journal for ImmunoTherapy of Cancer Open access 6 Feb 2019 82
13 Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer Tizita Zewde Zeleke et al. · Nature Cancer Open access 30 Dec 2022 81
14 Pbx Regulates Patterning of the Cerebral Cortex in Progenitors and Postmitotic Neurons Olga Golonzhka, Alex S. Nord, Paul Ling-Fung Tang et al. · Neuron Open access Dec 2015 72
15 Subpallial Enhancer Transgenic Lines: a Data and Tool Resource to Study Transcriptional Regulation of GABAergic Cell Fate Shanni N. Silberberg, Leila Taher, Susan Lindtner et al. · Neuron Open access Oct 2016 71
16 Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth Lawrence Van Helleputte, Mandy S. J. Kater, Dana Paulina Cook et al. · Neurobiology of Disease Open access 20 Dec 2017 70
17 Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY‐738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice Tabassum Majid, Deric M. Griffin, Zachary K. Criss et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access 9 Oct 2015 60
18 HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers Preeti Putcha, Jiyang Yu, Ruth Rodriguez Barrueco et al. · Breast Cancer Research Open access Dec 2015 58
19 First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma Jennifer Effie Amengual, Jennifer Kimberly Lue, Helen Ma et al. · The Oncologist Open access 18 Jan 2021 56
20 NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model Yan Liu, Yuyang Li, Shengwu Liu et al. · Cancer Research Open access 14 May 2018 52
21 Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor Brian J. North, Ingrid Almeciga-Pinto, David Tamang et al. · PLoS ONE Open access 6 Mar 2017 49
22 Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice Nicole L. Regna, Miranda D. Vieson, Xin Luo et al. · Clinical Immunology Open access 22 Nov 2015 48
23 Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study Mark Magdi Awad, Yvan Le Bruchec, Brian D. Lu et al. · Frontiers in Oncology Open access 6 Sep 2021 47
24 HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia S Tharkar-Promod, Danielle P. Johnson, Samuel E. Bennett et al. · Leukemia Open access 5 Jun 2017 45
25 Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2 Jeffrey R. Shearstone, Olga Golonzhka, Apurva Chonkar et al. · PLoS ONE Open access 13 Apr 2016 43
26 HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma Danielle P. Johnson, Gabriella S. Spitz, Shweta Tharkar et al. · Oncotarget Open access 31 Dec 2014 43
27 Histone deacetylase ( HDAC ) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC Sridurga Mithraprabhu, Tiffany T. Khong, Simon S. Jones et al. · British Journal of Haematology 21 May 2013 39
28 ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM) Noopur S Raje, Dan T. Vogl, Parameswaran Hari et al. · Blood 15 Nov 2013 26
29 Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia Kamira Karen Maharaj, John Joseph Powers, Alex N. Achille et al. · Blood Advances Open access 13 Nov 2018 25
30 Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study Noopur S Raje, Parameswaran Hari, Dan T. Vogl et al. · Blood 16 Nov 2012 25
31 Technology Applications: Use of Digital Health Technology to Enable Drug Development Joyce F. Liu, Jungmin Lee, Ellie S. Strock et al. · JCO Clinical Cancer Informatics Open access 29 Jun 2018 23
32 Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia Chengyin Min, Nathan W. Moore, Jeffrey R. Shearstone et al. · PLoS ONE Open access 6 Jan 2017 23
33 Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study) Noopur S Raje, William Bensinger, Craig Emmitt Cole et al. · Blood 3 Dec 2015 22
34 Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury Kerri D. Pryce, Randal A. Serafini, Aarthi Ramakrishnan et al. · Nature Neuroscience Open access 8 Jun 2023 21
35 Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice. Miranda D. Vieson, Alexander M. Gojmerac, Deena Khan et al. · PubMed Open access Dec 2017 21
36 ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study) Rubén Niesvizky, Paul Gerard Guy Richardson, Nashat Y. Gabrail et al. · Blood 3 Dec 2015 21
37 Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study) Rubén Niesvizky et al. · Blood 2 Dec 2016 20
38 Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM) Dan T. Vogl, Noopur S Raje, Parameswaran Hari et al. · Blood 6 Dec 2014 18
39 Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study) Dan T. Vogl, Noopur S Raje, Sundar Jagannath et al. · Blood 3 Dec 2015 18
40 Discovery of 6-aryl-azabenzimidaoles that inhibit the TBK1/IKK-ε kinases Jeffrey W. Johannes, Claudio E. Chuaqui, Scott D. Cowen et al. · Bioorganic & Medicinal Chemistry Letters Open access 13 Jan 2014 16
41 Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma Andrew Jenho Yee, Peter Michael Voorhees, William Bensinger et al. · Blood 6 Dec 2014 15
42 ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial Andrew Jenho Yee, Peter Vorhees, William Bensinger et al. · Blood 15 Nov 2013 15
43 ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM) Steven N. Quayle, Simon S Jones · Blood 15 Nov 2013 12
44 Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL) John Joseph Powers, Kamira Karen Maharaj, Eva Sahakian et al. · Blood 6 Dec 2014 11
45 Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study) Andrew Jenho Yee, William Bensinger, Peter Michael Voorhees et al. · Blood 3 Dec 2015 9
46 Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM) Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood 19 Nov 2010 8
47 Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Eva Sahakian, Jennifer A. Rock-Klotz, Bijal Dinesh Shah et al. · Blood 16 Nov 2012 8
48 HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease Sandra Bráz, Marlene M. Morgado, Marta Isabel Pereira et al. · Frontiers in Molecular Neuroscience Open access 27 Jul 2023 5
49 Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat Tizita Zewde Zeleke et al. · medRxiv PreprintOpen access 28 Apr 2020 5
50 The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG, ɣ) Expression in Monkey Apurva Chonkar, Matthew B. Jarpe, Kailash C. Bhol et al. · Blood 2 Dec 2016 5

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.